What drove NOVN.SW stock lower on 19 Mar 2026?

The drop to CHF116.88 was on higher-than-average volume (4,326,617 shares), reflecting profit-taking after recent gains and sector weakness. No single public catalyst was confirmed; watch Q1 earnings and clinical updates for confirmation.

What is the Meyka AI outlook for NOVN.SW stock?

Meyka AI projects a yearly price of CHF117.11 and a quarterly target of CHF137.85. The model implies modest near-term upside to the yearly figure and greater potential if catalysts arrive. Forecasts are projections, not guarantees.

Is NOVN.SW stock a buy after the pullback?

Novartis shows strong cash flow and a 3.10% dividend yield, with a B+ Meyka AI grade suggesting BUY. Consider staged buying around CHF110.00–120.00 and monitor earnings and regulatory news before adding size.

What technical levels matter for NOVN.SW stock traders?

Watch support near the 200-day average at CHF106.02 and resistance at the 50-day average CHF120.76. ATR is CHF2.46; RSI is 39.74, signalling room before oversold conditions.

CH Stocks

NOVN.SW Novartis AG (SIX) drops 4.02% on 19 Mar 2026: volume surge may offer tactical entry

ByDanny Kontos March 20, 2026March 20, 2026

Novartis AG (NOVN.SW) closed at CHF116.88 on 19 Mar 2026 after a -4.02% intraday drop on above-average volume. Today’s move put NOVN.SW stock among the most active names on the SIX, with 4,326,617 shares traded versus an average of 3,377,012. The fall follows a stretched 50-day average and leaves the price slightly below the 50-day mean of CHF120.76, while still above the 200-day mean of CHF106.02. We review fundamentals, technicals, Meyka AI grade and forecasts to frame short-term trading and longer-term investment possibilities.